Qiagen N.V. (QGEN)
NYSE: QGEN · IEX Real-Time Price · USD
41.65
+0.57 (1.39%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Qiagen Revenue
In the year 2023, Qiagen had annual revenue of $1.97B, a decrease of -8.23%. Revenue in the quarter ending December 31, 2023 was $509.16M with 2.24% year-over-year growth.
Revenue (ttm)
$1.97B
Revenue Growth
-8.23%
P/S Ratio
4.69
Revenue / Employee
$329,363
Employees
5,967
Market Cap
9.22B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
Dec 31, 2020 | 1.87B | 343.92M | 22.53% |
Dec 31, 2019 | 1.53B | 24.58M | 1.64% |
Dec 31, 2018 | 1.50B | 84.31M | 5.95% |
Dec 31, 2017 | 1.42B | 79.55M | 5.95% |
Dec 31, 2016 | 1.34B | 57.01M | 4.45% |
Dec 31, 2015 | 1.28B | -63.79M | -4.74% |
Dec 31, 2014 | 1.34B | 42.79M | 3.29% |
Dec 31, 2013 | 1.30B | 47.53M | 3.79% |
Dec 31, 2012 | 1.25B | 84.71M | 7.24% |
Dec 31, 2011 | 1.17B | 82.32M | 7.57% |
Dec 31, 2010 | 1.09B | 77.61M | 7.69% |
Dec 31, 2009 | 1.01B | 116.85M | 13.09% |
Dec 31, 2008 | 892.98M | 243.20M | 37.43% |
Dec 31, 2007 | 649.77M | 184.00M | 39.50% |
Dec 31, 2006 | 465.78M | 67.38M | 16.91% |
Dec 31, 2005 | 398.40M | 17.77M | 4.67% |
Dec 31, 2004 | 380.63M | 29.23M | 8.32% |
Dec 31, 2003 | 351.40M | 52.80M | 17.68% |
Dec 31, 2002 | 298.61M | 34.84M | 13.21% |
Dec 31, 2001 | 263.77M | 46.97M | 21.66% |
Dec 31, 2000 | 216.80M | 58.65M | 37.08% |
Dec 31, 1999 | 158.16M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tenet Healthcare | 20.56B |
Henry Schein | 12.34B |
Encompass Health | 4.80B |
AptarGroup | 3.49B |
Chemed | 2.26B |
Stevanato Group | 1.21B |
Repligen | 638.76M |
Ascendis Pharma | 296.35M |
QGEN News
- 3 days ago - QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance - GlobeNewsWire
- 18 days ago - QIAGEN N.V. to release results for Q1 2024 and hold webcast - GlobeNewsWire
- 24 days ago - QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024 - GlobeNewsWire
- 4 weeks ago - MyBio Are the New Exclusive Partner for QIAGEN in Ireland & Northern Ireland - Business Wire
- 4 weeks ago - QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system - GlobeNewsWire
- 5 weeks ago - QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements - GlobeNewsWire
- 6 weeks ago - QIAGEN announces Form 20-F annual report filing for 2023 results - GlobeNewsWire
- 2 months ago - QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery - GlobeNewsWire